Biotech | January 12, 2026
Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Subscribe To Our Newsletter & Stay Updated
